The Clinical Impact Of Gene Expression Assays On Early Luminal Breast Cancer

The clinical impact of gene expression assays on early luminal breast cancer

ROXANE: impact of 21-gene assay on treatment for early breast cancer

Gene expression assays to identify patients with breast cancer for neoadjuvant treatment

RxPONDER: 21-gene assay informs chemotherapy benefit in HR+ node-positive breast cancer

Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

The latest in neo-adjuvant therapy for luminal breast cancer

Molecular profiling in early breast cancer

Molecular Testing in Breast Cancer: Will it Become Standard Practice?

Agendia: The New Era of Genomic Testing in Early Stage Breast Cancer.

TAILORx: Phase 3 trial validating a 21-gene expression assay in breast cancer

Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes

SuperPathway Analyses of Luminal and Basaloid Breast Cancers... - Christopher Benz

National Human Genome Research Institute

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer

The genomic characterization of primary and metastatic HER2-low breast cancers

Development of Clinical Assay for Breast Cancer Using Invitrogen QuantiGene™ Plex Technology

The Role of Gene Expression Profiles in Determining Early Therapy in Breast Cancer.mp4

TCGA: The Molecular Diversity of Luminal A Breast Tumors - Giovanni Ciriello

National Human Genome Research Institute

Genomic Biomarker for Predicting Response in Early Breast Cancer Patients

2021 MDONS | The Nurses Role in Early Stage Breast Cancer | A Focus on Genomic Assays

Total Health | Oncology

The role of immunotherapy in endocrine-refractory luminal breast cancer